REGN — Regeneron Pharmaceuticals Share News
0.000.00%
Last trade - 00:00- $81.99bn
- $76.70bn
- $14.34bn
Brief: Regeneron Says FDA Approves Pasatru (Garetosmab-Grts) For Adults With Fibrodysplasia Ossificans Progressiva
US FDA approves Regeneron's rare bone disorder drug (updated)
US FDA approves Regeneron's rare bone disorder drug
EyePoint set for record drop after experimental eye drug misses study goal
EyePoint tumbles after experimental eye drug misses main goal in late-stage study
Brief: Infinimmune Raises $75 Million Series A Financing To Advance Pipeline Of Human-Derived Antibodies For Atopic Dermatitis And Inflammatory Disease
Brief: Regeneron Canada Says Libtayo Receives Health Canada Approval For Treatment Of A Type Of Carcinoma
U.S. STOCKS ON THE MOVE-Mastercard, Yum, Equinix
Regeneron Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
U.S. STOCKS ON THE MOVE-Mastercard, Starbucks, Meta
U.S. STOCKS ON THE MOVE-Avery Dennison, Huntington Ingalls, XPO
Regeneron beats quarterly estimates on eczema drug strength, shares rise
U.S. STOCKS ON THE MOVE-Fortinet, Regeneron, Cigna
Drug maker Regeneron gains after upbeat Q2 results
Regeneron Q2 revenue beats on higher Dupixent, Eylea HD sales
Brief: Regeneron Q2 Adjusted EPS USD 14.29 Vs. IBES Estimate USD 10.3
Sanofi drug pipeline worries, Dupixent dependence shake shares (updated)
Merck, Wellcome partner with global health group to make Ebola vaccine for clinical trials
Factbox: What Bundibugyo Ebola vaccines and treatments are under development